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 Abstract 
Normalising serum thyroid stimulating hormone (TSH) levels by lifelong treatment with 
levothyroxine (LT4) remains the primary goal of therapy for patients with hypothyroidism. The 
reference ranges for TSH are derived from populations with (supposedly) normal thyroid function. 
But, TSH results are affected by a number of factors including alterations in TSH levels with age, 
concurrent illnesses, circadian rhythm, inter- and intra-assay differences and some commonly-used 
medications that interfere with thyroid function or the TSH test. Furthermore, some patients are 
complex to manage and bringing serum TSH to within its reference range does not always resolve 
their symptoms of hypothyroidism. In others, changes in TSH within the reference range may 
provoke symptoms in some sensitive patients, and others may have a personal “set point” for 
thyroid hormone levels that represents normal function for that individual, but which is outside the 
population reference range.  The introduction of updated LT4 formulations, with better dosing 
accuracy and stability compared with older versions, should, in theory at least, provide better 
stability and accuracy of dosing over time. However, the new LT4 formulations were associated with 
manifold increases in the number of self-reported adverse events. Therefore; patients with 
hypothyroidism as well as the clinicians managing them need to better understand the utility as well 
as the limitations of the widely-used TSH measurement. In addition, both pharmaceutical companies 
and the prescribing clinician need to take greater care when patients are switched from older to 
newer formulations.   
Key words: levothyroxine; hypothyroidism; thyroid; thyroid stimulating hormone; narrow 
therapeutic index drug; new formulation 
Ac
ce
pte
d M
scr
ipt
 Introduction 
The thyroid gland secretes two principal hormones, triiodothyronine (T3) and thyroxine (T4), formed 
by deiodination of T3.1  A synthetic form of T4, levothyroxine (LT4), is the principal treatment for 
hypothyroidism, and blood levels of TSH serve as the principal biomarker of thyroid function 
according to current management guidelines in this area.2  While the majority of patients with 
hypothyroidism are managed successfully using normalisation of TSH during lifelong treatment with 
LT4, some are more difficult to manage, with apparent symptoms despite normalisation of TSH, or 
discordant results for tests of different thyroid hormones.  In this review we discuss the status and 
limitations of TSH testing and consider some practical implications of administering LT4 as a drug 
with a narrow therapeutic index, as defined by regulators. 
Thyroid stimulating hormone is the primary marker for establishing euthyroidism in a hypothyroid 
patient 
Why use TSH as the main biomarker for thyroid function? 
According to the guideline for the management of hypothyroidism from the American Thyroid 
Association (2014), the principal goals of management of hypothyroidism are normalisation of 
symptoms, signs and to normalise the level of TSH and to avoid over treatment.2  TSH is essentially 
an indirect measure of thyroid function: it is secreted from the pituitary gland and acts on the 
thyroid to increase secretion of thyroid hormones.  Abnormal TSH levels are common in the 
population: in the year 2002, the nationally representative US National Health and Examination 
Survey III cohort (1988–1994) found that 4.6 of community-dwelling individuals had hypothyroidism 
(ranging from about 2–14% depending on age and ethnicity).3 
The principal reason for using serum TSH, and not thyroid hormones per se, as the first-line test of 
thyroid function relates to the non-linear relationship between the levels of free thyroxine (FT4) and 
TSH.  Because of this relationship, a 2-fold alteration in the level of FT4 translates to a 10–100-fold 
change in the level of TSH.4  Accordingly, relatively large changes in TSH are more straightforward to 
measure routinely than relatively small changes in FT4 or free triiodothyronine (FT3).   
Hypothalamic/pituitary disorders can also affect thyroid function through abnormally low levels of 
TSH.5  These are rare (1 in 80–120,0005), and mostly due to tumours, or prior radiation therapy or 
surgery.5  Patients with central hypothyroidism may be under dosed with LT4, compared with 
patients with primary hypothyroidism.6  A detailed account of their diagnosis and management of 
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 hypothlamaic pituitary disorders is outside the scope of our review, and this has been reviewed 
elsewhere.7,8  
In summary, the level of TSH provides an appropriate index of thyroid function for most hypothyroid 
patients.  Bringing the TSH level back to within its reference range is usually the principal means 
employed by the physician to adjust the dose of LT4 for a patient with hypothyroidism. 
Limitations of TSH as a biomarker for thyroid function 
The TSH test has some limitations when used as a marker of thyroid status, and may be misleading in 
some other situations.  Inter-patient variations exist in relation to differences between the tests 
themselves, and in the clinical practices used to manage patients with suspected thyroid disease.9,10  
“Macro TSH”, a high molecular weight form of TSH, appears to be recognised variably by the assay 
methodologies used by commercial laboratories, and may provide another potentially important 
source of both inter-patient variation and discordance between the reported TSH level and the 
individual patient’s clinical thyroid status.11 
The test per se involves comparison of an individual patient’s TSH result with a reference range that 
has been defined across a population of apparently euthyroid subjects.  In the past, the populations 
used to define “normal” TSH have been contaminated with subjects with unknown thyroid disease, 
which distorted the upper limit of the reference range.12,13  The upper limit of reference ranges for 
TSH has reduced over time, from about 10 mIU/L to about 4–5 mIU/L, a development driven partly 
by the introduction of more sensitive and accurate TSH assays which can effectively exclude some of 
these outliers.12,14,15   
Nevertheless, the reference ranges for thyroid biomarkers are broad in physiological terms, having 
been defined across populations, while the variation of these markers in individual subjects appears 
to be much lower.16  Accordingly, variations in thyroid hormone levels of sufficient size to induce 
meaningful changes in thyroid function may not exceed the reference ranges.16,17  Individuals have 
their own “set points” for the operation of the hypothalamic-pituitary-thyroid axis that differ from 
the relationships between TSH and FT4 documented in populations.16,18  This means that, for 
example, an abnormal FT4 level may persist despite TSH being within the normal range, and a 
normal FT4 level for one patient may be abnormal for another, so that adjustment of TSH levels 
using LT4 in an attempt to corral thyroid marker levels within reference ranges may result in 
appropriate thyroid function for that individual.19  Levothyroxine therapy appears to shift the 
position of the set point over time, with a gradual reduction in the dose of LT4 required lower TSH 
(where elevated) although some of this change is due to ageing (see below).20   
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 Other limitations of the TSH test (excluding patients diagnosed with pituitary disorder or pituitary 
tumours) include unreliable readings due to non-thyroidal illness, recent treatment for 
thyrotoxicosis, concomitant treatments that interfere with thyroid hormone function or the TSH 
assay (including lithium, amiodarone, glucocorticoids, non-steroidal anti-inflammatory drugs and 
others), or disorders of thyroid hormone metabolism.19,21  Treatment with metformin has also been 
shown to reduce levels of TSH in euthyroid subjects,22 suggesting careful attention to thyroid 
function when starting, stopping or changing the dose of this widely-used antidiabetes agent.  
Adiposity may also modulate thyroid function: a study in 350 euthyroid subjects with morbid obesity 
demonstrated higher TSH and lower FT4 in those without anti-thyroid antibodies, compared with 
euthyroid subjects of normal weight.23  This study also showed that thyroid autoimmunity was less 
likely to account for the presence of autoimmunity in obese vs. normal weight subjects matched for 
TSH levels.  The impact of obesity on thyroid status is likely to become more important over time, as 
the prevalence and severity of obesity continues to increase in many populations.24  Thyroid 
hormone levels are subject to circadian and seasonal variations, which may give rise to variability of 
readings within a single subject.9  Thyroid hormone status also changes markedly during pregnancy 
(the thyroid increases in size and thyroid hormone secretion increases by about half at this time25) 
and with age: Fig. 1 shows an example of age-related reference ranges for TSH derived from a large 
community-dwelling population.26  The authors of this study speculated that the increase in the 
upper bound of the reference population with increasing age would be enough to reclassify a 
substantial (although not quantified) number of elderly patients from hypothyroid to euthyroid if 
these age-related ranges were used instead of the standard reference range for all ages.  
Clinical status of biochemically euthyroid patients  
A review of the clinical consequences of variations in thyroid hormones within the reference range 
concluded that there is evidence for significant association of renal dysfunction, weight gain, 
metabolic syndrome and other cardiovascular risk factors with higher TSH, and increased risk of 
osteoporosis and fractures associated with lower TSH.17  A large, recent meta-analysis of studies 
reporting thyroid status found that hypothyroid patients with normal TSH had significantly higher 
LDL-cholesterol and total cholesterol compared with controls without thyroid disease suggesting 
that normalisation of TSH according to current practice does not necessarily normalise markers of 
metabolism that are relevant to long-term clinical outcomes.27  A cross-sectional study from the 
same authors found that hypothyroid patients on LT4 treatment had higher body mass index, and 
-blockers and statins), compared with 
controls, despite normalisation of TSH.28   
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 The normalisation of symptoms of hypothyroidism by adjustment of TSH levels can be challenging, 
as these are often vague and nonspecific and develop over time.29  Indeed, the Colorado Thyroid 
Disease prevalence study found that more than half of euthyroid subjects reported at least one 
symptom consistent with thyroid disease, and about one in seven reported at least four such 
symptoms.3  Indicators suggestive of hypothyroidism, including dry skin, tiredness, subjectively poor 
memory/cognition and muscle symptoms, are frequently observed in both people who are 
euthyroid and in people with elevated TSH.29  Persistent symptoms of thyroid dysfunction appear to 
be common in a significant minority of hypothyroid patients managed with LT4.28,30  Administration 
of LT4 to patients with symptoms of hypothyroidism, but with thyroid hormones within reference 
ranges, had no effect relative to placebo on cognitive function and psychological wellbeing.31  A 
meta-analysis, in contrast found no benefit for quality of life or thyroid symptoms associated with 
management of subclinical hypothyroidism with LT4 replacement.32  Current guidelines from the 
American Thyroid Association counsel strongly against treatment with LT4 for people with 
hypothyroid-like symptoms despite normal biochemical indices of thyroid function.2  Careful 
evaluation of these patients is also required, to identify possible non-thyroid causes of these 
symptoms, often with a referral to secondary care.33   
LT4 is essentially a prodrug for triiodothyronine (T3) and in principle these hormones could be given 
in combination to a hypothyroid patient.  To date, however, administration of LT4 + T3 to patients 
with hypothyroidism has not provided convincingly superior results to administration of LT4 alone.34  
Debate continues as to what extent inappropriate dosing and other aspects of clinical trial design 
may have contributed to the disappointing outcome of these trials, and research continues, for 
example to identify subsets of patients who might benefit from this approach.34,35  For now, at least, 
clinical management guidelines and statements from expert societies do not support for addition of 
triiodothyronine to the regimens of such patients, especially within the primary care setting, as a 
positive benefit/risk balance for this strategy has yet to be demonstrated adequately.2,33,36,37 
Accuracy of dosing of levothyroxine 
How important are small variations in levothyroxine dosage? 
Minor fluctuations in thyroid hormones are often well tolerated by patients with hypothyroidism,38 
but certain groups of patients, for example the elderly (especially where coronary heart disease is 
present), pregnant women or patients with residual thyroid cancer after treatment may be 
especially sensitive to small changes in thyroid hormones.39  An unexplained apparent high level of 
sensitivity to changes in thyroid hormones may also be present in people without these conditions.39  
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 The US Endocrine Society has raised concerns about abrupt changes in doses of LT4 after switching 
of patients between LT4 preparations, even when these have satisfied formal criteria for 
bioequivalence with one another, as a result of the high level of sensitivity of the body to thyroid 
hormone levels.40  US guidelines recommend re-evaluation of thyroid status following a change of 
LT4 preparations, although this is acknowledged as a “weak recommendation” based on “low quality 
evidence”.2   
LT4 has been designated a “narrow therapeutic index” drug by regulatory authorities, on the basis of 
having “a risk of clinically relevant difference in efficacy or safety between two products even when 
the conventional criteria for bioequivalence … are met”.41  Accurate dosing is therefore important 
once the dosage is at or near the long-term maintenance dose.  Regulators increasingly require 
manufacturers of LT4 products to improve their formulations to support more accurate and 
consistent dosing, in order to minimise fluctuations in health status associated with variations in the 
actual dosage of LT4, either when switching between products of the same stated dose, or between 
batches of the same product.  Older product standards required the actual delivered dose of LT4 to 
lie within 90–100% of the stated dosage over the tablets’ entire shelf life (typically 3 years); a 
number of countries have tightened this specification to a range between 90% or 95% and 105%.42-44  
The new product must be bioequivalent with the old product, again to a tighter specification.  
Specifically, bioequivalence is usually achieved if geometric mean ratios and their 90% confidence 
intervals for key pharmacokinetic parameters (the area under the plasma concentration-time curve 
[AUC] and/or the maximal plasma concentration achieved [Cmax]) lie between 80% and 125%; the 
corresponding range for narrow therapeutic index drugs such as LT4 is 90–111%.41,45,46  As 
pharmacokinetic studies are carried out routinely in healthy volunteers, it is possible in principle that 
bioequivalence findings could differ in populations of patients with medical conditions.  We are 
unaware of clinical evidence of this phenomenon in patients receiving LT4 for hypothyroidism, 
however. 
Experience from the introduction of a new levothyroxine tablet consistent with newer regulatory 
guidance 
The introduction of a new formulation of a widely-prescribed formulation of LT4, developed to be 
consistent with evolving regulatory guidance in this area,47,48 provides a useful case study on the 
practicability of using such an updated preparation in routine patient care.  The new and old 
formulations are formally bioequivalent (under the “narrow therapeutic index drug” criteria, as 
described above, with full interchangeability between tablet strengths), and the amount of active 
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 LT4 remains within 95–105% of the labelled dose across its shelf life of 3 years, irrespective of the 
local climate.47   
Recently published pharmacovigilance reports, based on unsolicited reports of adverse events in 
France (the first country where the new formulation was launched), have been used to quantify the 
impact of the new formulation on hypothyroid patients who received the old and/or the new 
formulations of LT4.49  Some caution is required regarding the interpretation of this type of real-
world evidence, as information is often lacking on the time between switching and appearance of 
adverse events, TSH levels, medical history and comorbidity, and anonymous reports (accounting for 
most of the side-effects described in this analysis) cannot be followed up further.  The switch from 
old to new formulations was accompanied by a large (~150-fold) increase in the number of 
spontaneous reports of adverse events.  The proportion reporting new adverse events with the new 
formulation accounted for about 1.4% of users of this LT4 preparation in France.  Slightly more than 
half of patients had TSH levels in the normal range (where these data were available),49 which is 
consistent with real-world data from elsewhere.3  
Examination of individual side-effects revealed that most were consistent with the symptoms of 
hypothyroidism, and that no new safety signal had appeared after the switch to the new 
formulation.49  A large increase in spontaneous adverse event reporting occurred after the 
introduction of a different LT4 preparation in New Zealand in 2007–2008, which was also 
bioequivalent with its previous formulation.50  In both of these cases, social and broadcast media 
reporting of initial reports may have fuelled the growth in subsequent reports,49,50 and influenced 
the way that patients take the medication, as has been observed previously elsewhere for LT450,51 
and other drugs.52   
A dose-for-dose switch between LT4 preparations that are consistent with updated regulatory 
guidance on establishing bioequivalence should support continuity of thyroid function management 
without additional thyroid function testing beyond that required for the patient’s routine care.  The 
real world data described above show that the vast majority of patients switched between these 
formulations without new tolerability problems.  It is important to recognise that new strategies are 
needed in the age of social media to handle an increased rate of reporting of adverse events, in a 
way that allows clear identification of a new safety signal.  When, as in this case, regulators require a 
new formulation to be introduced, patients need to be briefed carefully by their healthcare 
practitioners on the reason for the change in their medicine, and how the new preparation relates to 
the old, to support continuity of their care. 
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 Conclusions 
Normalising the level of thyroid stimulating hormone remains the primary goal of therapy for 
patients with hypothyroidism.  A number of limitations relating to patient and disease factors apply 
to the use of TSH as the primary biomarker of thyroid function, however, and reports of patients 
with hypothyroid-like symptoms, despite within-range TSH, persist in real-world practice.  Patients 
often report changes in wellbeing after small changes in the dosage of LT4. Regulators are driving 
improvements in formulations of LT4, which provides opportunities for more stable, reproducible 
dosing, but also requires careful communication with patients and clinical teams to manage the 
switch. 
  
Ac
ce
pte
d M
an
us
cri
pt
 Transparency 
Declaration of funding   
This manuscript was sponsored by Merck KGaA. 
Declaration of financial/other relationships   
UG-H is an employee of Merck KGaA, the pharmaceutical sponsor of the updated LT4 preparation 
described above.  SR has acted as a speaker and member of advisory boards for Merck KGaA. Peer 
reviewers on this manuscript have received an honorarium from CMRO for their review work but 
have no other relevant financial relationships to disclose. 
Acknowledgements  
A medical writer (Dr Mike Gwilt, GT Communications, funded by Merck KGaA) provided editorial 
assistance. 
  
Ac
ce
pte
d M
an
us
cri
pt
 References 
1. Peeters RP, Visser TJ. Metabolism of thyroid hormone. In: Endotext [Internet], De Groot LJ, Chrousos 
G, Dungan K, et al., eds. 2000.  South Dartmouth (MA): MDText.com, Inc.  
2. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS et al. Guidelines for the treatment 
of hypothyroidism: prepared by the American Thyroid Association Task Force On Thyroid Hormone 
Replacement. Thyroid 2014;24:1670-751. 
3. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. 
Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National 
Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489-99. 
4. Rothacker KM, Brown SJ, Hadlow NC, Wardrop R, Walsh JP. Reconciling the log-linear and non-log-
linear nature of the TSH-free T4 relationship: intra-individual analysis of a large population. J Clin 
Endocrinol Metab 2016;101:1151-8. 
5. Gupta V, Lee M. Central hypothyroidism. Indian J Endocrinol Metab 2011; 15(Suppl2): S99–106. 
6. Koulouri O, Auldin MA, Agarwal R et al. Diagnosis and treatment of hypothyroidism in TSH deficiency 
compared to primary thyroid disease: pituitary patients are at risk of under-replacement with 
levothyroxine. Clin Endocrinol (Oxf) 2011;74:744-9. 
7. Beck-Peccoz P, Rodari G, Giavoli C, Lania A. Central hypothyroidism - a neglected thyroid disorder. 
Nat Rev Endocrinol 2017;13:588-598. 
8. Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL. 2013 European thyroid association 
guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J 
2013;2:76-82. 
9. Lin DC, Straseski JA, Schmidt RL, Various TTBG. Multi-center benchmark study reveals significant 
variation in thyroid testing in United States. Thyroid 2017 (in press, doi: 10.1089/thy.2017.0190). 
10. Hattori N, Ishihara T, Shimatsu A. Variability in the detection of macro TSH in different 
immunoassay systems. Eur J Endocrinol 2016;174:9-15. 
11. Spencer CA, Hollowell JG, Kazarosyan M, Braverman LE. National Health and Nutrition Examination 
Survey III thyroid-stimulating hormone (TSH)-thyroperoxidase antibody relationships demonstrate that 
TSH upper reference limits may be skewed by occult thyroid dysfunction. J Clin Endocrinol Metab. 
2007;92:4236-4240. 
12. Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. J 
Clin Endocrinol Metab 2005;90:5483-8. 
Ac
ce
pte
d M
an
us
cri
pt
 13. Hoermann R, Midgley JE. TSH measurement and its implications for personalised clinical decision-
making. J Thyroid Res 2012;2012:438037. 
14. Faix JD, Thienpont LM. Americal Association of Clinical Chemistry. Clin Lab News.  Available at 
https://www.aacc.org/publications/cln/articles/2013/may/tsh-harmonization (accessed November 
2018)’ 
15. Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T(4) and 
T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol 
Metab 2002;87:1068-72. 
16. Fitzgerald SP, Bean NG. The relationship between population T4/TSH set point data and T4/TSH 
physiology. J Thyroid Res. 2016;2016:6351473. 
17. Koulouri O, Moran C, Halsall D, Chatterjee K, Gurnell M. Pitfalls in the measurement and 
interpretation of thyroid function tests. Best Pract Res Clin Endocrinol Metab 2013;27:745-62. 
18. Verburg FA, Mäder U, Grelle I et al. The thyroid axis 'setpoints' are significantly altered after long-
term suppressive LT4 therapy. Horm Metab Res 2014;46:794-9. 
19. Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin 
Endocrinol Metab 2009;23:793-800. 
20. Andersen S, Bruun NH, Pedersen KM, Laurberg P. Biologic variation is important for interpretation 
of thyroid function tests. Thyroid 2003;13:1069-78. 
21. Stagnaro-Green A; Abalovich M; Alexander E et al. Guidelines of the American Thyroid Association 
for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 
2011;21:1081-125. 
22. Cappelli C, Rotondi M, Pirola I et al. Thyreotropin levels in diabetic patients on metformin 
treatment. Eur J Endocrinol 2012;167:261-5. 
23. Rotondi M, Leporati P, La Manna A et al. Raised serum TSH levels in patients with morbid obesity: 
is it enough to diagnose subclinical hypothyroidism? Eur J Endocrinol 2009;160:403-8. 
24. World health organization. Overweight and obesity.  Available at (accessed December 2018). 
25. Vadiveloo T, Donnan PT, Murphy MJ, Leese GP. Age- and gender-specific TSH reference intervals in 
people with no obvious thyroid disease in Tayside, Scotland: the Thyroid Epidemiology, Audit, and 
Research Study (TEARS). J Clin Endocrinol Metab 2013;98:1147-53.  
26. Taylor PN, Razvi S, Pearce SH, Dayan CM. Clinical review: A review of the clinical consequences of 
variation in thyroid function within the reference range. J Clin Endocrinol Metab 2013;98:3562-71. 
Ac
ce
pt
d M
an
us
cri
pt
 27. McAninch EA, Rajan KB, Miller CH, Bianco AC. Systemic thyroid hormone status during 
levothyroxine therapy in hypothyroidism: a systematic review and meta-analysis. J Clin Endocrinol 
Metab 2018.  
28. Peterson SJ, McAninch EA, Bianco AC. Is a normal TSH synonymous with "euthyroidism" in 
levothyroxine monotherapy? J Clin Endocrinol Metab 2016;101:4964-4973.  
29. Canaris GJ, Steiner JF, Ridgway EC. Do traditional symptoms of hypothyroidism correlate with 
biochemical disease? J Gen Intern Med 1997;12:544-50. 
30. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in 
patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based 
questionnaire study. Clin Endocrinol (Oxf) 2002;57:577-85. 
31. Pollock MA, Sturrock A, Marshall K, Davidson KM, Kelly CJ, McMahon AD, McLaren EH. Thyroxine 
treatment in patients with symptoms of hypothyroidism but thyroid function tests within the 
reference range: randomised double blind placebo controlled crossover trial. BMJ 2001;323:891-5. 
32. Feller M, Snel M, Moutzouri E et al. Association of thyroid hormone therapy with quality of life and 
thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-
analysis. JAMA 2018;320:1349-1359. 
33. National Institute for Health and Care Excellence.  Clinical knowledge Summaries. Hypothyroidism.  
Available at https://cks.nice.org.uk/hypothyroidism (accessed November 2018). 
34. Wiersinga WM. Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism. Nat 
Rev Endocrinol 2014;10:164-74. 
35. Hoermann R, Midgley JEM, Larisch R, Dietrich JW.  Lessons from randomised clinical trials for 
triiodothyronine treatment of hypothyroidism: have they achieved their objectives? J Thyroid Res 
2018;2018:3239197. 
36. Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP. 2012 ETA Guidelines: The Use of 
L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J 2012;1:55-71. 
37. Okosieme O, Gilbert J, Abraham P et al. Management of primary hypothyroidism: statement by the 
British Thyroid Association Executive Committee. Clin Endocrinol (Oxf). 2016;84:799-808. 
38. Walsh JP, Ward LC, Burke V et al. Small changes in thyroxine dosage do not produce measurable 
changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized 
clinical trial. J Clin Endocrinol Metab 2006;91:2624-30. 
39. Medicines and Healthcare Products Regulatory Agency. Levothyroxine: a review of clinical and 
quality considerations.  MHRA review of levothyroxine products in response to concerns about 
potential inconsistencies of different products. Available at 
Ac
ce
pte
d M
an
us
cri
pt
 https://www.gov.uk/government/publications/levothyroxine-a-review-of-clinical-and-quality-
considerations (accessed November 2018). 
40. Endocrine Society. Position Statement. Bioequivalence of sodium levothyroxine.  Available at 
https://www.endocrine.org/~/media/endosociety/files/advocacy-and-outreach/position-
statements/all/lt4positionstatementwithmembercommentsheader.pdf (accessed November 2018). 
41. European Medicines Agency.  Committee for Proprietary medicinal Products (CPMP).  Note for 
Guidance on the Investigation of Bioavailbility and Bioequivalence.  Available at 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC5000035
19.pdf (accessed September 2018).  
42. The United States Pharmacopeial Convention 2009 Current USP monograph of Levothyroxine 
Sodium Tablets (published in Revision Bulletin, Official February 1, 2010).  Available at (last accessed 
September 2010). 
43. Agence Française de Sécrurité Sanitaire des Produits de Santé 2012.  Commission Nationale de 
Pharmacovigilance. Compte rendu de la réunion du mardi 27 Mars 2012.  Available at 
https://ansm.sante.fr/var/ansm_site/storage/original/application/4e4d2a70e5dddfb150fe87360d6b1
3dd.pdf (accessed September 2012). 
44. Medicines and Health Regulatory Authority. Levothyroxine tablet products: a review of clinical & 
quality considerations.  07 January 2013.  Available at 
http://webarchive.nationalarchives.gov.uk/20141205150130/http:/www.mhra.gov.uk/home/groups/p
l-p/documents/drugsafetymessage/con222566.pdf (accessed September 2018). 
45. European Medicines Agency. Committee For Medicinal Products for Human Use (CHMP).  
Guideline on the Investigation of Bioequivalence.  Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1 (January 
2010).  Available at 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC5000700
39.pdf (accessed September 2018). 
46. Davit B, Braddy AC, Conner DP, Yu LX. International guidelines for bioequivalence of systemically 
available orally administered generic drug products: a survey of similarities and differences. AAPS J 
2013;15:974-90. 
47. Gottwald-Hostalek U, Uhl W, Wolna P, Kahaly GJ. New levothyroxine formulation meeting 95-105% 
specification over the whole shelf-life: results from two pharmacokinetic trials. Curr Med Res Opin 
2017;33:169-174. 
48. Lipp P, Hostalek U.  A new formulation of levothyroxine engineered to meet new specification 
standards.  Curr Med Res Opin 2018 (in press). 
Ac
ce
pt
d M
an
us
cri
pt
 49. Agence nationale de sécurité du médicament et des produits de santé.  Rapport final du 
25/01/2018.  Enquête officielle (2ème présentation). LEVOTHYROX® Levothyroxine, Laboratoire 
Merck. Présenté en Comité technique de pharmacovigilance le 30 janvier 2018.  Available at 
https://ansm.sante.fr/content/download/115249/1458453/version/2/file/Rapport_Levothyrox_CT-30-
01-2018.pdf (accessed December 2018). 
50. Faasse K, Cundy T, Petrie KJ. Medicine and the media. Thyroxine: anatomy of a health scare. BMJ 
2009;339:b5613. 
51. Kahan NR, Vardy DA, D-A Waitman, Brill G. A natural experiment in mass media modulated 
pharmacokinetics after a change in tablet formulation. Am J Manag Care 2013;19:e301-e308. 
52. Ben-Hamou M, Marshall NS, Grunstein RR, Saini B, Fois RA. Spontaneous adverse event reports 
associated with zolpidem in Australia 2001-2008. J Sleep Res 2011;20:559-68. 
 
 
Ac
ce
pte
d M
an
us
cri
pt
